OBJECTIVES: This study tested the hypothesis that response to antiarrhythmic drugs (AADs) is modulated by 3 common loci associated with atrial fibrillation (AF). BACKGROUND: Recent genome-wide association studies have identified 3 loci, on chromosomes 4q25 (near PITX2), 16q22 (in ZFHX3), and 1q21 (in KCNN3), that associate with either typical or lone AF. These findings indicate that variable mechanisms contribute to AF susceptibility, and suggest that response to therapy may be genotype dependent. METHODS: We studied 478 and 198 Caucasian patients in the discovery cohort and validation cohort, respectively, who were prospectively enrolled in the Vanderbilt AF registry. Response was defined prospectively as successful rhythm control if the patient remained on the same AAD therapy for a minimum of 6 months with ≥75% reduction in symptomatic AF burden. We also evaluated AF recurrence by 12-lead electrocardiogram (ECG) at 3, 6, and 12 months. Symptomatic patients were also given a 24- to 48-h Holter monitor or 30-day event recorder when AF recurrence was not captured by 12-lead ECG. RESULTS: In the discovery cohort, 399 (83%) patients were successfully rhythm controlled. Multiple clinical variables (including age, hypertension, lone AF) failed to significantly predict response to AADs; however, single nucleotide polymorphism (SNP) rs10033464 at 4q25 was an independent predictor of successful rhythm control in patients with typical AF carrying the ancestral allele (wild type) versus carriers of variant allele (odds ratio [OR]: 4.7, 95% confidence interval [CI]: 1.83 to 12, p = 0.0013. In the validation cohort, 143 (72%) patients met the criteria for successful rhythm control, and rs10033464 was again an independent predictor of successful rhythm control, OR: 1.5, 95% CI: 1.02 to 3.06, p = 0.04. This SNP (rs10033464) was an independent predictor of AF recurrence in the discovery (39% AF recurrence) and validation (38% AF recurrence) cohorts; OR: 3.27, 95% CI: 1.7 to 6, p < 0.001 and OR: 4.3, 95% CI: 1.98 to 9.4, p < 0.001, respectively. CONCLUSIONS: These results suggest that a common SNP on chromosome 4q25 associated with AF modulates response to AAD therapy and points to a potential role for stratification of therapeutic approaches by genotype.
OBJECTIVES: This study tested the hypothesis that response to antiarrhythmic drugs (AADs) is modulated by 3 common loci associated with atrial fibrillation (AF). BACKGROUND: Recent genome-wide association studies have identified 3 loci, on chromosomes 4q25 (near PITX2), 16q22 (in ZFHX3), and 1q21 (in KCNN3), that associate with either typical or lone AF. These findings indicate that variable mechanisms contribute to AF susceptibility, and suggest that response to therapy may be genotype dependent. METHODS: We studied 478 and 198 Caucasian patients in the discovery cohort and validation cohort, respectively, who were prospectively enrolled in the Vanderbilt AF registry. Response was defined prospectively as successful rhythm control if the patient remained on the same AAD therapy for a minimum of 6 months with ≥75% reduction in symptomatic AF burden. We also evaluated AF recurrence by 12-lead electrocardiogram (ECG) at 3, 6, and 12 months. Symptomatic patients were also given a 24- to 48-h Holter monitor or 30-day event recorder when AF recurrence was not captured by 12-lead ECG. RESULTS: In the discovery cohort, 399 (83%) patients were successfully rhythm controlled. Multiple clinical variables (including age, hypertension, lone AF) failed to significantly predict response to AADs; however, single nucleotide polymorphism (SNP) rs10033464 at 4q25 was an independent predictor of successful rhythm control in patients with typical AF carrying the ancestral allele (wild type) versus carriers of variant allele (odds ratio [OR]: 4.7, 95% confidence interval [CI]: 1.83 to 12, p = 0.0013. In the validation cohort, 143 (72%) patients met the criteria for successful rhythm control, and rs10033464 was again an independent predictor of successful rhythm control, OR: 1.5, 95% CI: 1.02 to 3.06, p = 0.04. This SNP (rs10033464) was an independent predictor of AF recurrence in the discovery (39% AF recurrence) and validation (38% AF recurrence) cohorts; OR: 3.27, 95% CI: 1.7 to 6, p < 0.001 and OR: 4.3, 95% CI: 1.98 to 9.4, p < 0.001, respectively. CONCLUSIONS: These results suggest that a common SNP on chromosome 4q25 associated with AF modulates response to AAD therapy and points to a potential role for stratification of therapeutic approaches by genotype.
Authors: Jun Wang; Elzbieta Klysik; Subeena Sood; Randy L Johnson; Xander H T Wehrens; James F Martin Journal: Proc Natl Acad Sci U S A Date: 2010-05-10 Impact factor: 11.205
Authors: Paulus Kirchhof; Peter C Kahr; Sven Kaese; Ilaria Piccini; Ismail Vokshi; Hans-Heinrich Scheld; Heinrich Rotering; Lisa Fortmueller; Sandra Laakmann; Sander Verheule; Ulrich Schotten; Larissa Fabritz; Nigel A Brown Journal: Circ Cardiovasc Genet Date: 2011-01-31
Authors: Mathilda T M Mommersteeg; Nigel A Brown; Owen W J Prall; Corrie de Gier-de Vries; Richard P Harvey; Antoon F M Moorman; Vincent M Christoffels Journal: Circ Res Date: 2007-09-06 Impact factor: 17.367
Authors: Robyn Otway; Jamie I Vandenberg; Guanglan Guo; Anthony Varghese; M Leticia Castro; Jian Liu; JingTing Zhao; Jane A Bursill; Ken R Wyse; Haley Crotty; Olivia Baddeley; Bruce Walker; Dennis Kuchar; Charles Thorburn; Diane Fatkin Journal: J Am Coll Cardiol Date: 2007-01-22 Impact factor: 24.094
Authors: Emelia J Benjamin; Kenneth M Rice; Dan E Arking; Arne Pfeufer; Charlotte van Noord; Albert V Smith; Renate B Schnabel; Joshua C Bis; Eric Boerwinkle; Moritz F Sinner; Abbas Dehghan; Steven A Lubitz; Ralph B D'Agostino; Thomas Lumley; Georg B Ehret; Jan Heeringa; Thor Aspelund; Christopher Newton-Cheh; Martin G Larson; Kristin D Marciante; Elsayed Z Soliman; Fernando Rivadeneira; Thomas J Wang; Gudny Eiríksdottir; Daniel Levy; Bruce M Psaty; Man Li; Alanna M Chamberlain; Albert Hofman; Ramachandran S Vasan; Tamara B Harris; Jerome I Rotter; W H Linda Kao; Sunil K Agarwal; Bruno H Ch Stricker; Ke Wang; Lenore J Launer; Nicholas L Smith; Aravinda Chakravarti; André G Uitterlinden; Philip A Wolf; Nona Sotoodehnia; Anna Köttgen; Cornelia M van Duijn; Thomas Meitinger; Martina Mueller; Siegfried Perz; Gerhard Steinbeck; H-Erich Wichmann; Kathryn L Lunetta; Susan R Heckbert; Vilmundur Gudnason; Alvaro Alonso; Stefan Kääb; Patrick T Ellinor; Jacqueline C M Witteman Journal: Nat Genet Date: 2009-07-13 Impact factor: 38.330
Authors: Patrick T Ellinor; Kathryn L Lunetta; Nicole L Glazer; Arne Pfeufer; Alvaro Alonso; Mina K Chung; Moritz F Sinner; Paul I W de Bakker; Martina Mueller; Steven A Lubitz; Ervin Fox; Dawood Darbar; Nicholas L Smith; Jonathan D Smith; Renate B Schnabel; Elsayed Z Soliman; Kenneth M Rice; David R Van Wagoner; Britt-M Beckmann; Charlotte van Noord; Ke Wang; Georg B Ehret; Jerome I Rotter; Stanley L Hazen; Gerhard Steinbeck; Albert V Smith; Lenore J Launer; Tamara B Harris; Seiko Makino; Mari Nelis; David J Milan; Siegfried Perz; Tõnu Esko; Anna Köttgen; Susanne Moebus; Christopher Newton-Cheh; Man Li; Stefan Möhlenkamp; Thomas J Wang; W H Linda Kao; Ramachandran S Vasan; Markus M Nöthen; Calum A MacRae; Bruno H Ch Stricker; Albert Hofman; André G Uitterlinden; Daniel Levy; Eric Boerwinkle; Andres Metspalu; Eric J Topol; Aravinda Chakravarti; Vilmundur Gudnason; Bruce M Psaty; Dan M Roden; Thomas Meitinger; H-Erich Wichmann; Jacqueline C M Witteman; John Barnard; Dan E Arking; Emelia J Benjamin; Susan R Heckbert; Stefan Kääb Journal: Nat Genet Date: 2010-02-21 Impact factor: 38.330
Authors: Babar Parvez; M Benjamin Shoemaker; Raafia Muhammad; Rachael Richardson; Lan Jiang; Marcia A Blair; Dan M Roden; Dawood Darbar Journal: Heart Rhythm Date: 2013-02-19 Impact factor: 6.343